Investigations from other laboratories have shown that LIMK1 can shuttle between the nucleus and cytoplasm, and that both nuclear and cytoplasmic LIMK1 could implicate breast cancer progression by activating the FAK/paxillin/Src/AKT/Erk pathway and therefore increasing FAK activation at focal adhesions [36,37]. Here, AKT1 is linked to breast cancer.